Zydus Cadilahas acquired Etna Biotech, a subsidiary of the Dutch biopharmaceutical company Crucell, for an undisclosed sum. Zydus expects the deal to catapult it to the forefront of innovation in vaccine R&D, and is the first acquisition by Zydus of a research firm.
Etna, which has its headquarters in Catania, Italy, focuses on the R&D of vaccines. It has several technologies and vaccines...